Read by QxMD icon Read


Rajsmita Bhattacharjee, Debajyoti Chatterjee, Tarun Narang, Sunil Dogra
No abstract text is available yet for this article.
July 17, 2018: Rheumatology
Gulnara Mamyrova, Takayuki Kishi, Ira N Targoff, Alison Ehrlich, Rodolfo V Curiel, Lisa G Rider
Objective: We examined features of clinically amyopathic JDM (CAJDM), in which patients have characteristic rashes with little to no evidence of muscle involvement, to determine whether this is a distinct phenotype from JDM. Methods: Demographic, clinical, laboratory and treatment data from 12 (9 hypomyopathic, 3 amyopathic) patients meeting modified Sontheimer criteria for CAJDM and from 60 matched JDM patients meeting Bohan and Peter criteria were examined. Differences were evaluated by Fisher's exact and Mann-Whitney tests, random forests and logistic regression analysis...
July 16, 2018: Rheumatology
Marie-Louise Hermansen, Benjamin Sandholt, Andreas Fuchs, Henrik Sillesen, Lars Køber, Klaus Fuglsang Kofoed, Mikkel Faurschou, Søren Jacobsen
Objective: To investigate the association between LN, renal function and atherosclerosis measured by coronary artery calcium (CAC) and carotid plaque in a cross-sectional study of patients with SLE. Methods: Presence of CAC and carotid plaque was measured in 147 SLE patients with and without LN. The patients were divided into four groups according to LN and renal function [by first quartile of estimated glomerular filtration rate (eGFR): 70 ml/min/1.73 m2]. Impaired renal function was defined by an eGFR <70 ml/min/1...
July 16, 2018: Rheumatology
Lise M Verhoef, Ellen M H Selten, Johanna E Vriezekolk, Alphons J L de Jong, Frank H J van den Hoogen, Alfons A den Broeder, Marlies E Hulscher
Objectives: The aim of this study was to identify the factors that play a role for patients with RA when considering dose reduction (i.e. gradual tapering until discontinuation) of biological DMARDs (bDMARDs), and to determine their relative importance. Methods: A mixed methods design was used in which we identified influencing factors by performing semi-structured interviews and ranked these factors using a Maximum Difference Scaling questionnaire. Also, we looked at the influence of several patient characteristics on this ranking...
July 13, 2018: Rheumatology
Frank Behrens, Michaela Koehm, Eva C Schwaneck, Marc Schmalzing, Holger Gnann, Gerd Greger, Hans-Peter Tony, Harald Burkhardt
Objective: The aim of this study was to evaluate minimal disease activity (MDA) assessments in patients with PsA during routine clinical care. Methods: We used data from a multicentre observational study of patients with active PsA who initiated treatment with adalimumab during routine clinical practice and continued treatment for at least 6 months to evaluate achievement of MDA, individual MDA criteria (modified to conform to study assessments) and ACR responses during 24 months of therapy...
July 13, 2018: Rheumatology
Pavel I Novikov, Ilya O Smitienko, Maria V Sokolova, Fatma Alibaz-Oner, Sema Kaymaz-Tahra, Haner Direskeneli, Sergey V Moiseev
Objectives: Certolizumab pegol (CZP) is a PEGylated antigen-binding fragment-fragment of a humanized mAb neutralizing TNF. It lacks Fc-fragment and has a very low potential to cross the placenta. We aimed to report the efficacy and safety of CZP in a case series of patients with refractory Takayasu arteritis (TA). Methods: Ten females of reproductive age (18-35 years) with TA were treated with CZP (at a dose of 400 mg at weeks 0, 2 and 4 and at 200 mg every 2 weeks thereafter) for a median of 10 months (range 3-28)...
July 12, 2018: Rheumatology
Giorgio Trivioli, Augusto Vaglio
No abstract text is available yet for this article.
July 12, 2018: Rheumatology
Derya Uluduz, Ipek Midi, Taskin Duman, Sena Colakoglu, Ahmet Tüfekci, Mustafa Bakar, Bijen Nazliel, Nida Tascilar, Baki Goksan, Mehmet Ali Sungur, Hasan Huseyin Kozak, Serkan Demir, Cemile Handan Misirli, Hayriye Kucukoglu, Nilgun Cinar, Fusun Mayda Domac, Serefnur Ozturk, Vildan Yayla, Ali Yavuz Karahan, Nazire Afsar, Eylem Ozaydin Goksu, Necdet Mengulluoglu, Emrah Aytac, Nilufer Yesilot, Birsen Ince, Ozgur Osman Yalin, Serdar Oruc, Seden Demirci, Mehmet Guney Senol, Arda Yilmaz, Mustafa Gokce, Özge Yilmaz Kusbeci, Gulnur Uzuner, Hale Zeynep Batur Caglayan, Mustafa Acikgoz, Burcu Zeydan, Fatih Ozdag, Sevim Baybas, Hakan Ekmekci, Murat Cabalar, Mehmet Yaman, Vedat Ali Yurekli, Hakan Tekeli, Hamit Genc, Uygar Utku, Firdevs Ezgi Ucan Tokuc, Nevzat Uzuner, Hesna Bektas, Yuksel Kablan, Basak K Goksel, Aysel Milanlioglu, Dilek Necioglu Orken, Ufuk Aluclu
Objective: This study was performed to determine the rate of cerebral venous sinus thrombosis (CVST) among cases of Behçet's disease (BD) included in a multicentre study of cerebral venous sinus thrombosis (VENOST). Methods: VENOST was a retrospective and prospective national multicentre observational study that included 1144 patients with CVST. The patients were classified according to aetiologic factors, time of CVST symptom onset, sinus involvement, treatment approach and prognosis...
July 9, 2018: Rheumatology
Sujith Subesinghe, Andrew Ian Rutherford, Rachel Byng-Maddick, Kimme Leanne Hyrich, James Benjamin Galloway
Objectives: To establish whether the decision to stop, continue or switch TNF inhibitor (TNFi) therapy to a biologic drug with an alternative mode of action following a serious infection (SI) impacts upon the risk of recurrent SI in patients with RA. Methods: Patients recruited to the British Society for Rheumatology Biologics Register-RA with at least one episode of SI while on TNFi were included. The biologic treatment decision following SI was considered. A multivariable adjusted Cox proportional hazards model was used to identify predictors of recurrent SI and whether biologic treatment choices influenced future SI risk...
July 6, 2018: Rheumatology
Agnes Zak, Cassandra Corrigan, Zhi Yu, Asaf Bitton, Liana Fraenkel, Leslie Harrold, Josef S Smolen, Daniel H Solomon
Objectives: Adherence to a treat to target (TTT) strategy is a recommended paradigm for RA; however, research shows there are many barriers to implementation. We conducted a trial to improve TTT implementation, and herein examine barriers to treatment adjustment within TTT among patient visits not in agreement with the TTT paradigm. Methods: Chart review assessed TTT implementation based on documentation of four items: designation of a treatment target, recording a disease activity measure, shared-decision making when applicable and adjusting treatment when disease activity was not at target...
July 5, 2018: Rheumatology
Gabriele De Marco, Dennis McGonagle, Hannah R Mathieson, Mira Merashli, Conor Magee, Oliver FitzGerald, Mark Goodfield, Helena Marzo-Ortega
No abstract text is available yet for this article.
July 4, 2018: Rheumatology
Kristine Rothaus Christensen, Mads Kjelgaard-Hansen, Lise Nikolic Nielsen, Bo Wiinberg, Frederik Alexander Althoehn, Niels Bloksgaard Poulsen, Kåre Kryger Vøls, Anders Popp Thyme, Karin Maria Lövgren, Axel Kornerup Hansen, Kirstine Roepstorff
Objectives: Detailed knowledge of the sequential cell and tissue responses following haemarthrosis is important for a deep understanding of the pathological process initiated upon extensive bleeding into the joint causing haemophilic arthropathy (HA). The underlying pathobiology driving haemarthrosis towards HA has been difficult to establish in detail, although animal models have shed light on some processes. Previous studies have focused on a single or a few distant time points and often only characterizing one tissue type of the joint...
July 3, 2018: Rheumatology
Valeria Manganelli, Serena Recalchi, Antonella Capozzi, Gloria Riitano, Vincenzo Mattei, Agostina Longo, Manuela Di Franco, Cristiano Alessandri, Michele Bombardieri, Guido Valesini, Roberta Misasi, Tina Garofalo, Maurizio Sorice
Objectives: Autophagy is a homeostatic and physiological process that promotes the turnover of proteins and organelles damaged in conditions of cellular stress. We previously demonstrated that autophagy represents a key processing event creating a substrate for autoreactivity, which is involved in post-translational changes and generation of citrullinated peptides, recognized by the immune system in RA. In this study, we analysed whether autophagy is involved in other post-translational changes that can generate autoantigens, focusing on carbamylation processes...
July 3, 2018: Rheumatology
Clément Lahaye, Zuzana Tatar, Jean-Jacques Dubost, Anne Tournadre, Martin Soubrier
The number of elderly people with chronic inflammatory rheumatic diseases is increasing. This heterogeneous and comorbid population is at particular risk of cardiovascular, neoplastic, infectious and iatrogenic complications. The development of biotherapies has paved the way for innovative therapeutic strategies, which are associated with toxicities. In this review, we have focused on the scientific and therapeutic changes impacting the management of elderly patients affected by RA, SpA or PsA. A multidimensional health assessment resulting in an integrated therapeutic strategy was identified as a major research direction for improving the management of elderly patients...
July 3, 2018: Rheumatology
Andrea Di Matteo, Emilio Filippucci, Edoardo Cipolletta, Iulia Satulu, Jana Hurnakova, Valentina Lato, Rossella De Angelis, Rudolf Horvath, Karel Pavelka, Fausto Salaffi, Walter Grassi
Objectives: The main objective of this study is to explore the prevalence and distribution of entheseal US changes in a cohort of SLE patients, taking as controls a group including both PsA patients and healthy subjects. The secondary objective is to investigate the correlation between the US findings and the clinical and serological data in SLE patients. Methods: Clinical and US assessment of quadriceps, patellar and Achilles tendons, and plantar fascia entheses were performed by independent rheumatologists on 65 patients with SLE, 50 patients with PsA and 50 healthy subjects...
July 3, 2018: Rheumatology
Natalia Pittman, Saara M Rawn, Mianbo Wang, Ariel Masetto, Karen A Beattie, Maggie Larché
Objectives: Almost all patients with SSc have gastrointestinal manifestations. Small intestinal bacterial overgrowth (SIBO) occurs in 30-60% of patients and leads to malnutrition and impaired quality of life. Recent systematic reviews have reported efficacy of treatments for SIBO, but these are not specific to patients with SSc. We conducted a systematic review of the evidence for all possible SIBO treatments in the SSc population. Methods: The following databases were searched: MEDLINE, EMBASE and the Cochrane Library, from database inception to 1 January 2017...
July 2, 2018: Rheumatology
Heidi L Munk, Dalia Fakih, Lene Christiansen, Qihua Tan, Anne F Christensen, Leif Ejstrup, Anne G Loft, Kirsten Junker, Kirsten O Kyvik, Rania Jounblat, Uffe Holmskov, Grith L Sorensen, Peter Junker
Objectives: Surfactant protein-D (SP-D), an innate immune defence molecule of the collectin family, is expressed in lungs and additional extrapulmonary epithelia. SP-D has immune modulatory and anti-microbial effects depending on its oligomerization. The ratio of high molecular weight (HMW): low molecular weight (LMW) SP-D in serum is mainly determined by the Met11Thr polymorphism (SNP rs721917). We aimed to study the SP-D serum level and the molecular size distribution in patients with untreated axial spondyloarthritis (axSpA) as compared with control subjects...
July 2, 2018: Rheumatology
Mark Yates, James Galloway, Marwan Bukhari
No abstract text is available yet for this article.
July 2, 2018: Rheumatology
Yannick Palmowski, Thomas Buttgereit, Frank Buttgereit
Seventy years ago, the first administration of cortisone in a patient with RA marked a milestone in the treatment of inflammatory diseases. However, the initial enthusiasm rapidly vanished as the administration of high doses for lengthy periods revealed worrisome adverse effects. It has taken several decades to overcome the (sometimes excessive) mistrust and to achieve a more differentiated evaluation of the benefit-risk profile and the adequate usage of glucocorticoids (GCs). Today, GCs remain indispensable for the treatment of many inflammatory conditions and their usefulness in RA as a disease-modifying low-dose co-medication is widely acknowledged...
July 2, 2018: Rheumatology
Gwenny M Verstappen, Rada V Moerman, Jolien F van Nimwegen, Martha S van Ginkel, Johan Bijzet, Esther Mossel, Arjan Vissink, Bouke P C Hazenberg, Suzanne Arends, Frans G M Kroese, Hendrika Bootsma
Objectives: Serum immunoglobulin free light chains (FLCs) are frequently elevated in B-cell-mediated autoimmune diseases, including primary SS (pSS). The objective of this study was to assess if serum FLCs can contribute to classification, mucosa-associated lymphoid tissue (MALT) lymphoma detection, monitoring of disease activity and treatment response in pSS. Methods: Serum samples of 100 consecutive patients suspected of pSS were included. Forty-five patients fulfilled ACR-EULAR criteria for pSS...
July 2, 2018: Rheumatology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"